Latest Breaking News On - Liz bodin - Page 1 : comparemela.com

Benralizumab Receives FDA Approval as Add-On Maintenance Therapy for Asthma

The FDA approval of benralizumab for patients ages 6 to 11 with asthma follows the conclusions of the phase 3 TATE study.

FDA Approves Benralizumab to Treat Pediatric Patients Aged 6 to 11 Years With Severe Asthma

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Additional indication for pediatric patients with severe eosinophilic asthma .

AstraZeneca (AZN) reports FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Benralizumab Receives FDA Approval as Add-On Maintenance Therapy for Children With Severe Asthma

The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study.